Why Immuneering Corporation’s (IMRX) Stock Is Up 5.77%
As of Wednesday, August 19, Immuneering Corporation’s IMRX share price has surged by 5.77%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Commentary & Analysis
Why Immuneering Corporation’s (IMRX) Stock Is Up 5.19%
As of Tuesday, August 11, Immuneering Corporation’s IMRX share price has surged by 5.19%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Immuneering Corporation’s (IMRX) Stock Is Down 5.50%
As of Friday, July 10, Immuneering Corporation’s IMRX share price has dipped by 5.50%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Immuneering Corporation’s (IMRX) Stock Is Up 8.43%
As of Wednesday, July 08, Immuneering Corporation’s IMRX share price has surged by 8.43%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Immuneering Corporation’s (IMRX) Stock Is Up 5.04%
As of Monday, June 29, Immuneering Corporation’s IMRX share price has surged by 5.04%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | IMRX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $324.8 | $288.9 | 32% |
|
| Shares Out (Mil) | 64.7 | 54.0 | 54% |
|
| Institutional Ownership | 78.0% | 93.1% | 47% |
|
| Float (Mil) | 49.2 | 41.4 | 47% |
|
| Beta | 0.37 | 0.94 | 21% |
|
| Avg Daily Volume (000s) | 543 | 480 | 61% |
|
| Price Change (52-week) |
(16.2%) | 59.9% | 33% |
|
| Growth | IMRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | (26.9%) | (10.1%) | 16% |
|
| EPS (5yr) | 18.0% | 15.9% | 64 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (14.9%) | (15.6%) | 53% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 7 | |
| Current EPS | ($0.306) | ($1.119) | ($1.256) | |
| Month Ago EPS | ($0.306) | ($1.113) | ($1.286) | |
| # Rev Up | 2 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.315) | ($1.137) | ($1.338) | |
| Year/Year Chg | 14.6% | (12.1%) | 18.2% | |
| Financials | IMRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($57) | ($43) | 15% |
|
| EPS (TTM) | ($0.980) | ($1.500) | 21% |
|
| Operating Cash Flow (TTM) (Mil) | ($57) | ($31) | 9% |
|
| Net Cash Flow (TTM) (Mil) | $15 | $2 | 60% |
|
| Long-Term Debt (Q1) (Mil) | $3 | $4 | 22% |
|
| Enterprise Value (Q1) (Mil) | $113 | $190 | 22% |
|
| Valuation | IMRX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.70 | 2.84 | 44% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | IMRX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (47.3%) | (47.7%) | 12% |
|
| ROE | (52.1%) | (55.0%) | 15% |
|
| Liabilities to Assets | 5.6% | 29.6% | 3% |
|
| F-Score | 3 | 3 | 18% |
|
Immuneering Corporation did not pass any screens on 9/2/2026.
